BRPI0514411A - formulação, e, método de produzir uma formulação - Google Patents

formulação, e, método de produzir uma formulação

Info

Publication number
BRPI0514411A
BRPI0514411A BRPI0514411-6A BRPI0514411A BRPI0514411A BR PI0514411 A BRPI0514411 A BR PI0514411A BR PI0514411 A BRPI0514411 A BR PI0514411A BR PI0514411 A BRPI0514411 A BR PI0514411A
Authority
BR
Brazil
Prior art keywords
formulation
producing
antagonist
seq
fusion protein
Prior art date
Application number
BRPI0514411-6A
Other languages
English (en)
Inventor
Daniel Dix
Katherine Bowers
Goolcharran Chimanlall
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0514411A publication Critical patent/BRPI0514411A/pt
Publication of BRPI0514411B1 publication Critical patent/BRPI0514411B1/pt
Publication of BRPI0514411B8 publication Critical patent/BRPI0514411B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULAçãO, E, MéTODO DE PRODUZIR UMA FORMULAçãO Proporciona-se formulações de um antagonista de interleucina-1 (IL-1) incluindo uma formulação pré-liofilizada, um formulação liofilizada reconstituída, e uma formulação líquida estável. De preferência, o antagonista de IL-1 é uma captação de IL-1 constituída de um dímero de duas proteínas de fusão apresentado uma seqüência de aminoácidos selecionada do grupo que consiste de SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, e 26. Da forma mais preferível, a proteína de fusão tem a seqüência da SEQ ID NO: 10.
BRPI0514411A 2004-08-17 2005-08-17 formulação, e, método de produzir uma formulação BRPI0514411B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60213704P 2004-08-17 2004-08-17
US60/602,137 2004-08-17
PCT/US2005/029428 WO2006023665A2 (en) 2004-08-17 2005-08-17 Il-1 antagonist formulations

Publications (3)

Publication Number Publication Date
BRPI0514411A true BRPI0514411A (pt) 2008-06-10
BRPI0514411B1 BRPI0514411B1 (pt) 2020-09-15
BRPI0514411B8 BRPI0514411B8 (pt) 2021-05-25

Family

ID=35968186

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514411A BRPI0514411B8 (pt) 2004-08-17 2005-08-17 formulação, e, método de produzir uma formulação

Country Status (15)

Country Link
US (1) US7365165B2 (pt)
EP (2) EP2311871A3 (pt)
JP (2) JP4948410B2 (pt)
CN (1) CN101014617B (pt)
AU (1) AU2005277357B2 (pt)
BR (1) BRPI0514411B8 (pt)
CA (1) CA2576519C (pt)
DK (1) DK1778723T3 (pt)
ES (1) ES2395035T3 (pt)
HK (1) HK1105421A1 (pt)
PL (1) PL1778723T3 (pt)
PT (1) PT1778723E (pt)
SI (1) SI1778723T1 (pt)
WO (1) WO2006023665A2 (pt)
ZA (1) ZA200701529B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
EP3470421B9 (en) 2010-07-29 2023-10-04 Buzzard Pharmaceuticals AB Chimeric il-1 receptor type i antagonists
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
RU2642664C2 (ru) 2011-11-18 2018-01-25 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
JP2014521602A (ja) 2012-04-04 2014-08-28 ポラリス グループ アルギニンデイミナーゼを用いる処置方法
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
RU2015143521A (ru) 2013-03-13 2017-04-19 Илэвэн Байотерапьютикс, Инк. Лекарственные формы химерных цитокинов для глазной доставки
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
EP4186523A1 (en) 2016-09-16 2023-05-31 Leukocare AG A novel method for stabilization of a biopharmaceutical drug product during processing
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JP3822383B2 (ja) * 1993-12-17 2006-09-20 持田製薬株式会社 可溶性トロンボモジュリン含有組成物
DE69620877T2 (de) * 1995-02-06 2002-12-12 Genetics Inst Arzneimittelformulierungen für il-12
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP4172842B2 (ja) * 1997-05-02 2008-10-29 生化学工業株式会社 コンドロイチナーゼ組成物
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
ATE404176T1 (de) * 2003-01-08 2008-08-15 Novartis Vaccines & Diagnostic Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors

Also Published As

Publication number Publication date
AU2005277357B2 (en) 2011-08-04
PL1778723T3 (pl) 2013-03-29
CN101014617B (zh) 2011-03-30
HK1105421A1 (en) 2008-02-15
BRPI0514411B8 (pt) 2021-05-25
WO2006023665A2 (en) 2006-03-02
EP1778723A2 (en) 2007-05-02
EP1778723B1 (en) 2012-11-14
WO2006023665A3 (en) 2006-08-03
DK1778723T3 (da) 2012-12-03
EP2311871A3 (en) 2012-08-08
AU2005277357A1 (en) 2006-03-02
CA2576519A1 (en) 2006-03-02
BRPI0514411B1 (pt) 2020-09-15
ZA200701529B (en) 2008-09-25
SI1778723T1 (sl) 2013-02-28
PT1778723E (pt) 2013-01-25
CA2576519C (en) 2013-05-21
US7365165B2 (en) 2008-04-29
JP2008510716A (ja) 2008-04-10
JP4948410B2 (ja) 2012-06-06
ES2395035T3 (es) 2013-02-07
JP2012121894A (ja) 2012-06-28
US20060040852A1 (en) 2006-02-23
EP2311871A2 (en) 2011-04-20
CN101014617A (zh) 2007-08-08

Similar Documents

Publication Publication Date Title
BRPI0514411A (pt) formulação, e, método de produzir uma formulação
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
BR0208183A (pt) Peptìdeo modificado por wt1
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ES2354824T3 (es) Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
DE602005010246D1 (de) Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration
ATE427925T1 (de) Phenoxycarbonsaureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
PE20080339A1 (es) Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento
UA95235C2 (en) Glucagon-like-peptide-2 (glp-2) analogues
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
HK1113970A1 (en) Formulations for injection of catecholic butanes, including ndga compounds, into animals
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
BR9811094A (pt) Agente terapêutico para tumores linfáticos
DE50211566D1 (de) Kombination ausgewählter opioide mit muscarin-antagonisten zur therapie der harninkontinenz
ATE252375T1 (de) Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2736 DE 13-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.